Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7396 to 7410 of 7675 results

  1. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development [GID-TA11301] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065

    In development [GID-TA11588] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued [GID-TA11396]

    Technology appraisal guidance
    Discontinued

  4. PICO negative pressure wound therapy for closed surgical incision wounds (MIB149)

    This advice has been updated and replaced by NICE medical technologies guidance 43.

    Medtech innovation briefing
    Published
    15 June 2018

  5. QAngio XA 3D/QFR imaging software for assessing coronary obstructions (MIB146)

    This advice has been updated and replaced by NICE diagnostics guidance 43.

    Medtech innovation briefing
    Published
    15 May 2018

  6. Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke (MIB141)

    This medtech innovation briefing (MIB) has been updated and replaced by NICE diagnostics guidance 41.

    Medtech innovation briefing
    Published
    16 February 2018

  7. Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)

    This advice has been replaced by NICE diagnostics guidance 37.

    Medtech innovation briefing
    Published
    18 January 2018

  8. Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

    In development [GID-TA10826] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    In development [GID-TA11044] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    In development [GID-TA11411] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development [GID-TA11165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued [GID-TA10750]

    Technology appraisal guidance
    Discontinued

  13. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development [GID-TA10758] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Psoriatic arthritis in adults: certolizumab pegol (ESNM42)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.

    Evidence summary
    Published
    24 June 2014

  15. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-TA11569] Expected publication date: TBC

    Technology appraisal guidance
    In development